Premium
Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study
Author(s) -
Keller Nicolas,
Duquennoy Simon,
Conrad Anne,
FafiKremer Samira,
Morelon Emmanuel,
Bouvier Nicolas,
Moulin Bruno,
Hurault De Ligny Bruno,
Caillard Sophie
Publication year - 2019
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13058
Subject(s) - leflunomide , medicine , immunosuppression , tolerability , retrospective cohort study , renal function , bk virus , adverse effect , kidney transplantation , transplantation , urology , gastroenterology , methotrexate
Background BK polyomavirus associated nephropathy (BKPyVAN) is a significant clinical issue in kidney transplant (KT) recipients. No specific therapy is currently available, although treatment with leflunomide may be part of the therapeutic strategy. Here, we sought to examine the impact of leflunomide on the evolution of BKPyVAN. Methods This was an observational retrospective study conducted in 3 French transplant centers. KT recipients who developed BKPyVAN and received leflunomide after failure of other treatment approaches were deemed eligible. Graft function, viral clearance, patient survival, rejection rates, treatment tolerability, and immunosuppression levels served as the main outcome measures. Results A total of 55 patients were included. Treatment with leflunomide was started after a mean of 1.4 ± 4.1months after BKPyVAN diagnosis. Between the introduction of leflunomide and the end of follow‐up, creatinine levels increased by 31 ± 118% ( P = 0.04), whereas viremia decreased by 79 ± 37% ( P < 0.001). Blood viral clearance was observed in 76% of the study patients. Rejection episodes occurred in 33% of the participants. Eleven patients lost their graft (9 of which because of BKPyVAN). Ten patients developed adverse effects and 3 discontinued leflunomide. Conclusion We cannot conclude about the exact place of leflunomide in the therapeutic strategy of BKPyVAN. It may be a part of the therapy to promote BK polyomavirus clearance in cases of BKPyVAN who fail to improve after immunosuppression lowering alone. Unfortunately, a significant decline in renal function and high rejection rates remain major clinical challenges.